[go: up one dir, main page]

WO2001009303A3 - Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER - Google Patents

Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER Download PDF

Info

Publication number
WO2001009303A3
WO2001009303A3 PCT/US2000/020679 US0020679W WO0109303A3 WO 2001009303 A3 WO2001009303 A3 WO 2001009303A3 US 0020679 W US0020679 W US 0020679W WO 0109303 A3 WO0109303 A3 WO 0109303A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
flt
ligand
encoding
vertebrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/020679
Other languages
French (fr)
Other versions
WO2001009303A2 (en
Inventor
Gary George Hermanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Publication of WO2001009303A2 publication Critical patent/WO2001009303A2/en
Publication of WO2001009303A3 publication Critical patent/WO2001009303A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a pharmaceutical composition, comprising a first non-infectious, non-integrating nucleic acid molecule construct comprising a polynucleotide encoding a Flt-3 ligand, and a second non-infectious, non-integrating nucleic acid molecule construct comprising a polynucleotide encoding an antigen or a cytokine. The present invention also provides a method broadly directed to enhancing immune response of a vertebrate in need of immunotherapy which entails administering in vivo, into a tissue of a vertebrate, a Flt-3 ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides. The polynucleotides are incorporated into the cells of the vertebrate in vivo, and a prophylactically or therapeutically effective amount of a Flt-3 ligand and one or more antigens is produced in vivo.
PCT/US2000/020679 1999-07-30 2000-07-31 Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER Ceased WO2001009303A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14617099P 1999-07-30 1999-07-30
US60/146,170 1999-07-30

Publications (2)

Publication Number Publication Date
WO2001009303A2 WO2001009303A2 (en) 2001-02-08
WO2001009303A3 true WO2001009303A3 (en) 2001-08-16

Family

ID=22516137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020679 Ceased WO2001009303A2 (en) 1999-07-30 2000-07-31 Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER

Country Status (1)

Country Link
WO (1) WO2001009303A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
US20030017529A1 (en) * 2001-06-27 2003-01-23 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
WO2003083083A2 (en) * 2002-03-26 2003-10-09 Immunex Corporation Methods of using flt3-ligand in immunization protocols
CA2511927A1 (en) * 2002-12-27 2004-08-12 Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. Method of preparing a vaccine and anti-tumor vaccines
US7504243B2 (en) 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
JP6251477B2 (en) 2009-12-02 2017-12-20 イマジナブ・インコーポレーテッド J591 minibody and CYS diabody targeting human prostate specific membrane antigen (PSMA) and methods for using them
US9101557B2 (en) 2011-04-13 2015-08-11 Auburn University Combination of protein forms for hornfly vaccination
JP7026613B2 (en) 2015-08-07 2022-02-28 イマジナブ・インコーポレーテッド Antigen binding construct for target molecule
US11058752B2 (en) * 2016-11-22 2021-07-13 Alloplex Biotherapeutics Allogeneic tumor cell vaccine
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
CN110338153B (en) * 2019-07-15 2021-08-03 杭州森康林业科技有限公司 A method for immobilizing pine xylophilus parasites for microinjection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012633A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation Dendritic cell stimulatory factor
WO1999026663A2 (en) * 1997-11-20 1999-06-03 Vical, Inc. Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012633A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation Dendritic cell stimulatory factor
WO1999026663A2 (en) * 1997-11-20 1999-06-03 Vical, Inc. Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN KEYUE ET AL: "Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model.", CANCER RESEARCH, vol. 57, no. 16, 1997, pages 3511 - 3516, XP002159231, ISSN: 0008-5472 *
FERNANDEZ N ET AL: "ACTIVE SPECIFIC T-CELL-BASED IMMUNOTHERAPY FOR CANCER: NUCLEIC ACIDS, PEPTIDES, WHOLE NATIVE PROTEINS, RECOMBINANT VIRUSES, WITH DENDRITIC CELL ADJUVANTS OR WHOLE TUMOR CELL-BASED VACCINES. PRINCIPLES AND FUTURE PROSPECTS", CYTOKINES, CELLULAR AND MOLECULAR THERAPY,MARTIN DUNITZ PUBLISHERS, LONDON,GB, vol. 4, no. 1, March 1998 (1998-03-01), pages 53 - 65, XP000857807, ISSN: 1368-4736 *
MCCLANAHAN TERRILL ET AL: "Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand.", BLOOD, vol. 88, no. 9, 1996, pages 3371 - 3382, XP000979439, ISSN: 0006-4971 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
US9527919B2 (en) 2007-09-04 2016-12-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection

Also Published As

Publication number Publication date
WO2001009303A2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
WO2001009303A3 (en) Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
WO2005007673A3 (en) Immunogenic peptides
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
JP2003528155A5 (en)
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
WO2002034205A3 (en) Using heat shock proteins to increase immune response
EP2325205A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2004064759A3 (en) Use of tryptanthrin compounds for immune potentiation
WO2001026681A3 (en) Method of obtaining cellular immune responses from proteins
EP1659178A3 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
WO2002080965A3 (en) Vaccine composition
WO2003012072A3 (en) Monoclonal antibodies to activated erbb family members and methods of use thereof
RU2007142645A (en) METHOD FOR TREATING OR PREVENTING CANCER BY USING COMPOSITIONS CONTAINING ALPHA-2-MACROGLOBULIN
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
WO2001095919A3 (en) A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
DE69637571D1 (en) COMPOSITION AND METHOD FOR REINFORCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS
US7408050B2 (en) Modified CpG oligodeoxynucleotide with improved immunoregulatory function
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
WO2002032378A3 (en) Fusion cells and cytokine compositions for treatment of disease
CA2360382A1 (en) Use of antibodies for the vaccination against cancer
WO2002053176A3 (en) An autologous anti-cancer vaccine
EP1801123A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2001000231A3 (en) Use of cpg as an adjuvant for malaria vaccine
WO2003093298A3 (en) Immunogenic peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP